Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Dec;24(12):2364-2366.
doi: 10.1002/ejhf.2674. Epub 2022 Sep 15.

Unravelling the role of sex in the pathophysiology, phenotypic expression and diagnosis of cardiac amyloidosis

Claudio Rapezzi  1   2 , Michele Emdin  3 , Alberto Aimo  3
Affiliations
Free article
Editorial

Unravelling the role of sex in the pathophysiology, phenotypic expression and diagnosis of cardiac amyloidosis

Claudio Rapezzi et al. Eur J Heart Fail. 2022 Dec.
Free article

Abstract

Sex-related differences in amyloid transthyretin (ATTR) amyloidosis.

PubMed Disclaimer

Comment on

  • Sex differences among patients with transthyretin amyloid cardiomyopathy - from diagnosis to prognosis.
    Patel RK, Ioannou A, Razvi Y, Chacko L, Venneri L, Bandera F, Knight D, Kotecha T, Martinez-Naharro A, Masi A, Porcari A, Brown J, Patel K, Manisty C, Moon J, Rowczenio D, Gilbertson JA, Sinagra G, Lachmann H, Wechalekar A, Petrie A, Whelan C, Hawkins PN, Gillmore JD, Fontana M. Patel RK, et al. Eur J Heart Fail. 2022 Dec;24(12):2355-2363. doi: 10.1002/ejhf.2646. Epub 2022 Aug 16. Eur J Heart Fail. 2022. PMID: 36575133 Free PMC article.

References

    1. Leone O, Boriani G, Chiappini B, Pacini D, Cenacchi G, Martin Suarez S, et al. Amyloid deposition as a cause of atrial remodelling in persistent valvular atrial fibrillation. Eur Heart J. 2004;25:1237-41.
    1. Röcken C, Peters B, Juenemann G, Saeger W, Klein HU, Huth C, et al. Atrial amyloidosis: an arrhythmogenic substrate for persistent atrial fibrillation. Circulation. 2002;106:2091-7.
    1. González-López E, Gagliardi C, Dominguez F, Quarta CC, de Haro-Del Moral FJ, Milandri A, et al. Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths. Eur Heart J. 2017;38:1895-904.
    1. Zampieri M, Argirò A, Allinovi M, Tassetti L, Zocchi C, Gabriele M, et al. Sex-related differences in clinical presentation and all-cause mortality in patients with cardiac transthyretin amyloidosis and light chain amyloidosis. Int J Cardiol. 2022;351:71-7.
    1. Campbell CM, LoRusso S, Dispenzieri A, Kristen AV, Maurer MS, Rapezzi C, et al. Sex differences in wild-type transthyretin amyloidosis: an analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS). Cardiol Ther. 2022;11:393-405.

Supplementary concepts